Literature DB >> 3663461

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.

R E Durand1, D J Chaplin.   

Abstract

Misonidazole has been demonstrated to enhance the cytotoxicity of several common antineoplastic drugs in vitro and in vivo, and its mechanism of action as a chemosensitizer, though still unknown, is thought to be dependent upon hypoxia. We have used fluorescence-activated cell sorting to evaluate chemopotentiation by misonidazole as a function of cell position in V79 spheroids and KHT tumours. CCNU toxicity was enhanced in all cell subpopulations of both tumours and spheroids, with greater consistency than might be predicted on the basis of the known variations in oxygen tension. Further, both misonidazole and CCNU as single agents were preferentially toxic in the less well oxygenated regions of each system, arguing that differential toxicity cannot be implicated in the chemopotentiation observed. In fact, increased treatment toxicity did not necessarily lead to increased chemopotentiation, nor was potentiation directly related to the metabolism/binding of the misonidazole. Chemopotentiation in multicell systems thus appears to be a complex, multi-factorial process.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663461      PMCID: PMC2002149          DOI: 10.1038/bjc.1987.165

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Damage to mammalian cell DNA by nitrofurans.

Authors:  P L Olive; D R McCalla
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

2.  Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells.

Authors:  B A Moore; B Palcic; L D Skarsgard
Journal:  Radiat Res       Date:  1976-09       Impact factor: 2.841

3.  Use of Hoechst 33342 for cell selection from multicell systems.

Authors:  R E Durand
Journal:  J Histochem Cytochem       Date:  1982-02       Impact factor: 2.479

4.  Development of a 9L rat brain tumor cell multicellular spheroid system and its response to 1,3-bis(2-chloroethyl)-1-nitrosourea and radiation.

Authors:  D F Deen; T Hoshino; M E Williams; I Muraoka; K D Knebel; M Barker
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

5.  The cytocidal action of metronidazole in combination with other antineoplastic agents.

Authors:  J P Kelly; T W Hannam; G R Giles
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

6.  Radiation response of multicell spheroids--an in vitro tumour model.

Authors:  R M Sutherland; R E Durand
Journal:  Curr Top Radiat Res Q       Date:  1976-01

7.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

8.  Cross-link formation and chemopotentiation of EMT-6/Ro cells exposed to MISO after CCNU treatment in vitro.

Authors:  R T Mulcahy
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

9.  A marker for hypoxic cells in tumours with potential clinical applicability.

Authors:  J D Chapman; A J Franko; J Sharplin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

10.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

View more
  3 in total

1.  Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents.

Authors:  M V Papadopoulou; A Mainwaring; W D Bloomer
Journal:  Jpn J Cancer Res       Date:  1992-08

2.  Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo.

Authors:  C Grau; S M Bentzen; J Overgaard
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

3.  Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

Authors:  P J O'Dwyer; F P LaCreta; J Walczak; T Cox; S Litwin; J P Hoffman; M Zimny; R L Comis
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.